Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -49.76% is 29% above its 5-year average of -69.68%, near the high end of its 5-year range (-323.50%–-26.99%).
As of the fiscal period ended Tuesday, June 30, 2026. 18.37% below its 12-month average of -42.04%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -49.76%.
RETURN ON INVESTED CAPITAL (ROIC)
-49.76%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-42.04%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-62.51%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-69.68%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-52.88%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-50.72%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-56.41%
CURRENT VS TTM AVG
-18.37%
CURRENT VS 3Y AVG
+20.39%
CURRENT VS 5Y AVG
+28.58%
CURRENT VS 10Y AVG
+5.89%
CURRENT VS 15Y AVG
+1.90%
CURRENT VS 20Y AVG
+11.78%
SECTOR MEDIAN · HEALTHCARE
-33.61%
median of 724 covered companies
CURRENT VS SECTOR MEDIAN
-48.03%
vs the sector median at left
Abeona Therapeutics Inc.
Market Cap
$287.55M
Return on Invested Capital (ROIC)
-49.76%
TTM Avg
-42.04%
3Y Avg
-62.51%
5Y Avg
-69.68%
Market Cap
$288.15M
Return on Invested Capital (ROIC)
-20.40%
TTM Avg
-43.02%
3Y Avg
-57.92%
5Y Avg
-48.43%
Market Cap
$288.27M
Return on Invested Capital (ROIC)
-14.06%
TTM Avg
-26.07%
3Y Avg
-28.37%
5Y Avg
-26.89%
Market Cap
$288.34M
Return on Invested Capital (ROIC)
-61.10%
TTM Avg
-38.45%
3Y Avg
-31.16%
5Y Avg
-81.63%
Market Cap
$285.37M
Return on Invested Capital (ROIC)
-129.90%
TTM Avg
-509.42%
3Y Avg
-303.54%
5Y Avg
-247.13%
Market Cap
$282.68M
Return on Invested Capital (ROIC)
-27.62%
TTM Avg
-16.38%
3Y Avg
-32.77%
5Y Avg
-39.71%
Market Cap
$295.61M
Return on Invested Capital (ROIC)
-136.49%
TTM Avg
-130.82%
3Y Avg
-85.38%
5Y Avg
-76.42%
Market Cap
$279.05M
Return on Invested Capital (ROIC)
-15.69%
TTM Avg
-4.06%
3Y Avg
-9.73%
5Y Avg
-12.88%
Market Cap
$277.96M
Return on Invested Capital (ROIC)
-31.62%
TTM Avg
-73.81%
3Y Avg
-69.44%
5Y Avg
-42.80%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abeona Therapeutics Inc. (ABEO) | $287.55M | -49.76% | -42.04% | -62.51% | -69.68% |
| Sagimet Biosciences Inc. (SGMT)vs › | $288.15M | -20.40% | -43.02% | -57.92% | -48.43% |
| Standard BioTools Inc. (LAB)vs › | $288.27M | -14.06% | -26.07% | -28.37% | -26.89% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $288.34M | -61.10% | -38.45% | -31.16% | -81.63% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | -129.90% | -509.42% | -303.54% | -247.13% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | -27.62% | -16.38% | -32.77% | -39.71% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.61M | -136.49% | -130.82% | -85.38% | -76.42% |
| Aurora Cannabis Inc. (ACB)vs › | $279.05M | -15.69% | -4.06% | -9.73% | -12.88% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.96M | -31.62% | -73.81% | -69.44% | -42.80% |
| Fate Therapeutics, Inc. (FATE)vs › | $275.66M | -58.72% | -52.25% | -49.23% | -41.07% |
ROIC
-49.8%
ROE
-49.1%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -49.76% |
| 2026-03-31 | -51.23% |
| 2025-12-31 | -44.17% |
| 2025-09-30 | -38.04% |
| 2025-06-30 | -26.99% |
| 2025-03-31 | -77.75% |
| 2024-12-31 | -65.34% |
| 2024-09-30 | -56.98% |
| 2024-06-30 | -47.53% |
| 2024-03-31 | -78.53% |
| 2023-12-31 | -93.19% |
| 2023-09-30 | -81.25% |
| 2023-06-30 | -101.81% |
| 2023-03-31 | -92.24% |
| 2022-12-31 | -90.22% |
| 2022-09-30 | -323.50% |
| 2022-06-30 | -290.40% |
| 2022-03-31 | -223.72% |
| 2021-12-31 | -142.68% |
| 2021-09-30 | -62.31% |
| 2021-06-30 | -54.15% |
| 2021-03-31 | -47.27% |
| 2020-12-31 | -74.31% |
| 2020-09-30 | -68.11% |
| 2020-06-30 | -73.69% |
| 2020-03-31 | -76.77% |
| 2019-12-31 | -41.74% |
| 2019-09-30 | -61.34% |
| 2019-06-30 | -56.00% |
| 2019-03-31 | -44.69% |
| 2018-12-31 | -37.05% |
| 2018-09-30 | -32.55% |
| 2018-06-30 | -23.21% |
| 2018-03-31 | -19.64% |
| 2017-12-31 | -16.08% |
| 2017-09-30 | -26.77% |
| 2017-06-30 | -26.75% |
| 2017-03-31 | -23.19% |
| 2016-12-31 | -23.24% |
| 2016-09-30 | -36.11% |
| 2016-06-30 | -36.42% |
| 2016-03-31 | -30.77% |
| 2015-12-31 | -23.60% |
| 2015-09-30 | -14.50% |
| 2015-06-30 | -9.64% |
| 2015-03-31 | -32.04% |
| 2014-12-31 | -22.23% |
| 2008-09-30 | -1312.90% |
| 2008-06-30 | -268.82% |
| 2008-03-31 | -175.60% |
| 2007-12-31 | -53.04% |
| 2007-06-30 | -630.76% |
| 2007-03-31 | -206.18% |
| 2006-12-31 | -116.40% |
| 2006-09-30 | -194.93% |
| 2006-06-30 | -130.54% |
| 2006-03-31 | -114.33% |
| 2005-12-31 | -215.89% |
| 2005-09-30 | -235.65% |
| 2005-06-30 | -207.71% |
| 2005-03-31 | -104.61% |
| 2004-12-31 | -102.26% |
| 2004-09-30 | -86.16% |
| 2004-06-30 | -67.99% |
| 2004-03-31 | -53.57% |
| 2003-12-31 | -96.22% |
| 2003-09-30 | -73.97% |
| 2003-06-30 | -67.17% |
